Literature DB >> 21518185

South Australian clinical registry for metastatic colorectal cancer.

Eu Ling Neo1, Carol Beeke, Timothy Price, Guy Maddern, Chris Karapetis, Colin Luke, David Roder, Robert Padbury.   

Abstract

INTRODUCTION: The aims of the South Australian Clinical Registry for Metastatic Colorectal Cancer are to record case outcomes according to site of recurrence and mode of clinical practice and to utilize the accumulated information for quality assurance activities.
METHODS: All patients who had a diagnosis of synchronous or metachronous metastatic colorectal cancer (CRC) after 1 February 2006 were eligible to be included in the registry. Data on patient details, disease characteristics, investigations, histopathology and treatment were collected. Disease-specific survival data were assessed using Kaplan-Meier product moment estimates and the log-rank test of equality was used for comparisons.
RESULTS: 1544 patients have been entered as of 22 March 2010. In addition, 54.7% of primary CRCs were in the rectosigmoid area, 92.9% of them adenocarcinomas. Also, 52.6% of patients received chemotherapy and 15% had radiotherapy. Two hundred five patients underwent liver resection, nine had radiofrequency ablation and seven had selective internal radiotherapy. The overall 3-year survival from time of diagnosis of metastatic CRC was 29.5%. There was no significant survival difference between patients with synchronous and metachronous metastatic CRC. Patients with lung- or liver-only metastases have significantly improved survival if they underwent surgical resection. DISCUSSION: The treatment of patients with metastatic CRC continues to progress with modern medical and surgical developments. Important insights into the current patterns of care and clinical outcomes for metastatic CRC are provided by these data. In addition, this registry provides a feasible and useful database for the evaluation of current treatments established as best evidence in this population.
© 2010 The Authors. ANZ Journal of Surgery © 2010 Royal Australasian College of Surgeons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21518185     DOI: 10.1111/j.1445-2197.2010.05589.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  9 in total

1.  Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study.

Authors:  S Yousuf Zafar; Jennifer L Malin; Steven C Grambow; David H Abbott; Jane T Kolimaga; Leah L Zullig; Jane C Weeks; John Z Ayanian; Katherine L Kahn; Patricia A Ganz; Paul J Catalano; Dee W West; Dawn Provenzale
Journal:  Cancer       Date:  2012-09-12       Impact factor: 6.860

2.  BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

Authors:  Timothy J Price; Carol Beeke; Amanda Rose Townsend; Louisa Lo; Roy Amitesh; Robert Padbury; David Roder; Guy Maddern; James Moore; Christos Karapetis
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

3.  Error rates in a clinical data repository: lessons from the transition to electronic data transfer--a descriptive study.

Authors:  Matthew K H Hong; Henry H I Yao; John S Pedersen; Justin S Peters; Anthony J Costello; Declan G Murphy; Christopher M Hovens; Niall M Corcoran
Journal:  BMJ Open       Date:  2013-05-28       Impact factor: 2.692

4.  Microwave Ablation and Immune Activation in the Treatment of Recurrent Colorectal Lung Metastases: A Case Report.

Authors:  Magnus Bäcklund; Jacob Freedman
Journal:  Case Rep Oncol       Date:  2017-04-27

5.  Systematic failure to operate on colorectal cancer liver metastases in California.

Authors:  Mustafa Raoof; Zeljka Jutric; Sidra Haye; Philip H G Ituarte; Beiqun Zhao; Gagandeep Singh; Laleh Melstrom; Susanne G Warner; Bryan Clary; Yuman Fong
Journal:  Cancer Med       Date:  2020-07-20       Impact factor: 4.452

6.  The Validity of Registered Synchronous Peritoneal Metastases from Colorectal Cancer in the Danish Medical Registries.

Authors:  Sissel Ravn; Christian F Christiansen; Rikke H Hagemann-Madsen; Victor J Verwaal; Lene H Iversen
Journal:  Clin Epidemiol       Date:  2020-03-27       Impact factor: 4.790

7.  Adjuvant oxaliplatin-based chemotherapy effect after treatment of colorectal hepatic metastasis.

Authors:  Mee-Young Kang; Jin-Hee Paik; Chun-Geun Ryu; Dae-Yong Hwang
Journal:  Ann Surg Treat Res       Date:  2021-08-31       Impact factor: 1.859

8.  Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.

Authors:  Gargi S Patel; Shahid Ullah; Carol Beeke; Paul Hakendorf; Robert Padbury; Timothy J Price; Christos S Karapetis
Journal:  Cancer Med       Date:  2015-07-25       Impact factor: 4.452

9.  Overall risk and risk factors for metachronous peritoneal metastasis after colorectal cancer surgery: a nationwide cohort study.

Authors:  S Ravn; U Heide-Jørgensen; C F Christiansen; V J Verwaal; R H Hagemann-Madsen; L H Iversen
Journal:  BJS Open       Date:  2020-01-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.